Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
TLDR
Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
View on PubMed
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
TLDR
The multidisciplinary approach adopted at institutions is described, and recommendations for monitoring, grading, and managing the acute toxicities that can occur in patients treated with CAR-T-cell therapy are provided.
View on Wolters Kluwer
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
TLDR
Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
View on PubMed
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
TLDR
Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects.
View on PubMed
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
TLDR
BCL2 is a valid therapeutic target in CLL, and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease.
View on PubMed
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
TLDR
In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.
View on PubMed
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
TLDR
FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.
View on PubMed
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
TLDR
According to the experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL.
View on PubMed
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
TLDR
Evidence is provided that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.
View on PubMed
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License